Online inquiry

IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4513MR)

This product GTTS-WQ4513MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CXCL10 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001565.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3627
UniProt ID P02778
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4513MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6585MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DC-1630423
GTTS-WQ8768MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ4547MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ13141MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ3032MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ6396MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ5281MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD124
GTTS-WQ552MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 4D5-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW